Expert review of neurotherapeutics · 2025
Physician experience and perceptions of tetrabenazine for the treatment of tardive dyskinesia and Huntington's chorea: a survey of neurologists and psychiatrists.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sung Victor W, Claassen Daniel O, Ribalov Rinat, Yaari Ayelet, Guillaume Xavier, Le Calvé Perrine, Peyser Levin Aviva, Kim Manho, Gurevich Tanya
Аннотация
BACKGROUND: This study assessed neurologists' and psychiatrists' experience with and perceptions of tetrabenazine (TBZ) when treating patients with tardive dyskinesia (TD) and Huntington disease (HD)-related chorea.
RESEARCH DESIGN AND METHODS: Neurologists and psychiatrists from Australia and Israel who manage TD, and neurologists from Australia, Israel, and South Korea who manage HD-related chorea, answered 20-minute anonymous online questionnaires.
RESULTS: A total of 72 neurologists and psychiatrists managing patients with TD and 24 neurologists managing patients with HD-related chorea were included. Among physicians who had experience with TBZ (TD, n = 62; HD, n = 20), most (61%; 80%) were moderately satisfied with TBZ for treatment of TD/HD-related chorea, some were dissatisfied (23%; 10%), and only 17% and 10% were very/extremely satisfied. Additionally, 18% and 25% reported that they were often/almost always unable to titrate TBZ to optimal doses because of side effects and 24% and 15% reported that side effects often/almost always led to TBZ discontinuation.
CONCLUSION: Although most physicians were moderately satisfied with TBZ, they also reported that TBZ side effects prevented reaching optimal clinical effectiveness and often led to discontinuation, suggesting a need for additional effective treatment options with favorable benefit-risk profiles for TD and HD-related chorea.
RESEARCH DESIGN AND METHODS: Neurologists and psychiatrists from Australia and Israel who manage TD, and neurologists from Australia, Israel, and South Korea who manage HD-related chorea, answered 20-minute anonymous online questionnaires.
RESULTS: A total of 72 neurologists and psychiatrists managing patients with TD and 24 neurologists managing patients with HD-related chorea were included. Among physicians who had experience with TBZ (TD, n = 62; HD, n = 20), most (61%; 80%) were moderately satisfied with TBZ for treatment of TD/HD-related chorea, some were dissatisfied (23%; 10%), and only 17% and 10% were very/extremely satisfied. Additionally, 18% and 25% reported that they were often/almost always unable to titrate TBZ to optimal doses because of side effects and 24% and 15% reported that side effects often/almost always led to TBZ discontinuation.
CONCLUSION: Although most physicians were moderately satisfied with TBZ, they also reported that TBZ side effects prevented reaching optimal clinical effectiveness and often led to discontinuation, suggesting a need for additional effective treatment options with favorable benefit-risk profiles for TD and HD-related chorea.